PHII-95 Randomized, Phase II Trial of AZD6244 Alone and AZD6244 plus Temsirolimus for Soft-Tissue Sarcomas.

Trial Profile

PHII-95 Randomized, Phase II Trial of AZD6244 Alone and AZD6244 plus Temsirolimus for Soft-Tissue Sarcomas.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Selumetinib (Primary) ; Temsirolimus
  • Indications Leiomyosarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 03 Jun 2014 Primary endpoint 'Progression-free-survival-duration' has not been met.
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top